Medicare Enrolled
Dr. Lois Kamugisha
Medical Oncology · Northampton, MA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kamugisha from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kamugisha?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kamugisha
Dr. Lois Kamugisha is a medical oncology specialist in Northampton, MA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Kamugisha performed 32,890 Medicare services across 666 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kamugisha received a total of $4,612 from 40 pharmaceutical and/or device companies across 200 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kamugisha is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 1% volume in MA
$4,612 industry payments
Medicare Practice Summary
Medicare Utilization ↗32,890
Medicare services
Top 1% in MA for medical oncology
666
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,827 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
24,750 | $1 | $2 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
2,290 | $6 | $15 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,910 | $36 | $67 |
| Denosumab injection (Prolia/Xgeva) | 1,620 | $18 | $32 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
750 | $6 | $12 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
322 | $0 | $0 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
311 | $12 | $63 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
310 | $101 | $202 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
104 | $55 | $225 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
64 | $18 | $70 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
62 | $71 | $70 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
58 | $112 | $478 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
55 | $25 | $100 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
35 | $1 | $3 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
32 | $21 | $120 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
30 | $19 | $45 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
29 | $13 | $59 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $138 | $305 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
28 | $1 | $3 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
23 | $11 | $45 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
23 | $66 | $136 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
23 | $143 | $355 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
19 | $140 | $270 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
13 | $1 | $1 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
82.0% high complexity
16.4% medium
1.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,612
Total received (2022-2024)
Avg $1,537/year across 3 years
Top 49% in MA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
200
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,211 (91.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$401 (8.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,084
2023
$2,852
2022
$676
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$217
Celgene Corporation
$104
Rigel Pharmaceuticals, Inc.
$91
JAZZ PHARMACEUTICALS INC.
$62
E.R. Squibb & Sons, L.L.C.
$56
AstraZeneca Pharmaceuticals LP
$54
Daiichi Sankyo Inc.
$52
Bayer Healthcare Pharmaceuticals Inc.
$50
Exelixis Inc.
$43
Merck Sharp & Dohme LLC
$39
PharmaEssentia USA Corporation
$38
Novocure Inc.
$35
Takeda Pharmaceuticals U.S.A., Inc.
$33
Mirati Therapeutics, Inc.
$30
Incyte Corporation
$28
Astellas Pharma US Inc
$27
Gilead Sciences, Inc.
$26
ADC Therapeutics America, Inc.
$22
SOBI, INC
$22
Janssen Biotech, Inc.
$21
Myriad Genetic Laboratories, Inc.
$17
GENZYME CORPORATION
$16
Top 3 companies account for 38.0% of 2024 payments
All-time payments by company (2022-2024) ›
Novartis Pharmaceuticals Corporation
$590
Myriad Genetic Laboratories, Inc.
$376
Gilead Sciences, Inc.
$309
Janssen Biotech, Inc.
$295
E.R. Squibb & Sons, L.L.C.
$260
Rigel Pharmaceuticals, Inc.
$248
Merck Sharp & Dohme LLC
$213
JAZZ PHARMACEUTICALS INC.
$194
AstraZeneca Pharmaceuticals LP
$193
Celgene Corporation
$168
Incyte Corporation
$134
EISAI INC.
$125
Bayer Healthcare Pharmaceuticals Inc.
$121
GENZYME CORPORATION
$120
Mirati Therapeutics, Inc.
$112
Exelixis Inc.
$99
Lilly USA, LLC
$94
Takeda Pharmaceuticals U.S.A., Inc.
$91
PFIZER INC.
$90
Pharmacyclics LLC, An AbbVie Company
$83
Seagen Inc.
$82
Genentech USA, Inc.
$64
Daiichi Sankyo Inc.
$64
PharmaEssentia USA Corporation
$62
Kite Pharma, Inc.
$56
Astellas Pharma US Inc
$55
Amgen Inc.
$47
BeiGene USA, Inc.
$35
Novocure Inc.
$35
Bayer HealthCare Pharmaceuticals Inc.
$24
ADC Therapeutics America, Inc.
$22
Alexion Pharmaceuticals, Inc.
$22
SOBI, INC
$22
Blueprint Medicines Corporation
$21
GlaxoSmithKline, LLC.
$18
MorphoSys, US Inc.
$18
Coherus Biosciences Inc.
$17
Telix Pharmaceuticals
$16
Paratek Pharmaceuticals, Inc.
$13
Organon LLC
$3
Top 3 companies account for 27.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BESREMI · BOSULIF · BRUKINSA · CABOMETYX · CALQUENCE · DARZALEX · DOPTELET · ELITEK · EMGALITY · ENHERTU · ERLEADA · EVENITY · Enhertu · FRUZAQLA · Fabhalta · GAZYVA · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Lenvima · MEKINIST · MONJUVI · MYRISK · NINLARO · NUZYRA · Nplate · Nubeqa · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · Optune Lua (NovoTTF-200T) · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · Phesgo · Pomalyst · REBLOZYL · Rezlidhia · SARCLISA · SCEMBLIX · Stivarga · TAGRISSO · TALVEY · TASIGNA · TRINTELLIX · TUKYSA · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · VERZENIO · XALKORI · Xospata · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (91%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
10
Per 100K population
6.4
County median income
$86,391
Nearest hospital
NORTHAMPTON VA MEDICAL CENTER
4.9 mi
4.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kamugisha is a mixed practice specialist, with above-average Medicare volume (top 1% in MA), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kamugisha experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Kamugisha performed 24,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kamugisha receive payments from pharmaceutical companies?
Yes. Dr. Kamugisha received a total of $4,612 from 40 companies across 200 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kamugisha's costs compare to other medical oncologists in Northampton?
Dr. Kamugisha's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kamugisha) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Northampton
Browse medical oncologists in Northampton ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in MA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in MA
Which MA medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology